The application of this therapeutic strategy may result in a higher selectivity against the PTEN‐deficient tumor cells relative to PTEN wild‐type cells and, therefore, in a wider therapeutic window of the treatments compared to the more complete inhibition of different points on the PI3K pathway by a pan‐PI3K, AKT, or mTOR inhibitor. This evidence concerns the gene PIK3CD and neoplasm.